COMPLEX PROBLEMS OF TREATMENT OF INFLAMMATORY BOWEL DISEASES IN REAL-LIFE CLINICAL PRACTICE
https://doi.org/10.17238/PmJ1609-1175.2019.3.76-79
Abstract
Objective to analyze the effectiveness of therapy with the use of genetically engineered biologic drugs (GEBD) in patients with moderate and severe forms of ulcerative colitis (UC) and Crohn’s disease (CD).
Methods: The study was done based on gastroenterological department of PRCH No. 1. The effectiveness of treatment was assessed with retrospective analysis of 29 case records. The severity of the disease was evaluated according to the Mayo Score and the Harvey–Bradshaw index. Following biologic therapy drugs were used: anti-tumor necrosis factor α agent and integrin blocking agent ‘Vedolizumab’. Clinical response and endoscopic dynamics were included. Data was processed with software Statistica 10.
Results: 20 patients were diagnosed with CD, 9 patients – with UC. Mean age of patients is 37.2 y.o. Initially all patients received standard immunomodulatory therapy. Development of resistance to steroids and steroid-dependence, and also ineffectiveness of immunosuppressive drugs became an indication to use GEBD. Positive clinical response was observed right after the first infusion in 24 patients. After 10-14 weeks of treatment positive clinical response was recorded in 58.6 % of cases. After 24–28 weeks of treatment clinical remission rate with endoscopic view improvement was in 24.1 %, and total clinical endoscopic remission rate was 17.2 %. Therapy improvement was required in 17.2 % of cases.
Conclusions: The use of GEBD has advantages in clinical and endoscopic remission in treatment of patients with refractory types of UC and CD.
About the Authors
E. Yu. Evdokimova
Pacific State Medical University
Russian Federation
Russian Federation
2 Ostryakova Ave. Vladivostok 690002 Russian Federation
O. V. Chesnokova
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
I. L. Mukhina
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
T. B. Andreeva
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
A. S. Moskalenko
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
O. V. Saik
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
N. A. Belova
Primorye Regional Clinical Hospital No. 1
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
Russian Federation
57a Aleutskaya St. Vladivostok 690950 Russian Federation
References
1. Van Assche G., Dignass A., Bokemeyer B. [at al.]. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease for the European Crohn’s and Colitis Organisation (ECCO) // Journal of Crohn,s and Colitis. 2012. doi: 10.1016/j.crohns.2012.09.005
2. Clinical Guide of Russian Association of Gastroenterology and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis // Koloproktologiya. 2017. No. 1. P. 6–30.
3. Molodecky N.A., Soon I.S., Rabi D.M. [et al.]. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review // Gastroenterology. 2012. Vol. 42, No. 1. P. 46–54.
4. Inflammatory bowel diseases: Current opportunities and unresolved problems in drug therapy // Consilium Medicum. Gastroenterology (Suppl.). 2015. No. 1. P. 33–34.
5. Yarur A.J., Strobel S.J., Deshpande A.R., Abreu M.T. Predictors of aggressive inflammatory bowel disease // Gastroenterol. Hepatol. 2011. Vol. 7, No. 10. Р. 652–659.
6. Clinical Guide of Russian Association of Gastroenterology and Russian Association of Coloproctology on diagnostics and treatment of Crohn’s disease // Koloproktologiya. 2017. No. 2. P. 7–29.
7. Van Assche G., Dignass A., Bokemeyer B. [at al.]. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease for the European Crohn’s and Colitis Organisation (ECCO) // Journal of Crohn,s and Colitis. 2012. doi: 10.1016/j.crohns.2012.09.005
8. Clinical Guide of Russian Association of Gastroenterology and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis // Koloproktologiya. 2017. No. 1. P. 6–30.
9. Knyazev O.V., Shkurko T.V., Fadeyeva N.A. [et al.]. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow // Experimental and Clinical Gastroenterology Journal. 2017. No. 3. P. 4–12.
10. Clinical Guide of Russian Association of Gastroenterology and Russian Association of Coloproctology on diagnostics and treatment of Crohn’s disease // Koloproktologiya. 2017. No. 2. P. 7–29.
11. Yarur A.J., Strobel S.J., Deshpande A.R., Abreu M.T. Predictors of aggressive inflammatory bowel disease // Gastroenterol. Hepatol. 2011. Vol. 7, No. 10. Р. 652–659.
12. Knyazev O.V., Shkurko T.V., Fadeyeva N.A. [et al.]. Epidemiology of chronic inflammatory bowel disease. Yesterday, today, tomorrow // Experimental and Clinical Gastroenterology Journal. 2017. No. 3. P. 4–12.
13. Kushnir І.Е. Therapeutic treatment strategies of ulcerative colitis: realities and future // Modern Gastroenterology. 2016. No. 4. P. 108–115.
14. Kushnir І.Е. Therapeutic treatment strategies of ulcerative colitis: realities and future // Modern Gastroenterology. 2016. No. 4. P. 108–115.
15. Parfenov A.I., Knyazev O.V., Kagramanova A.V., Fadeeva N.A. Personalized medicine in the treatment of inflammatory bowel disease // Therapeutic archive. 2018. No. 2. P. 4–11.
16. Parfenov A.I., Knyazev O.V., Kagramanova A.V., Fadeeva N.A. Personalized medicine in the treatment of inflammatory bowel disease // Therapeutic archive. 2018. No. 2. P. 4–11.
17. Tkachev A.V., Mkrtchyan L.S., Nikitina K.E., Volynskaya E.I. Inflammatory bowel disease: Crossing of the problems // Prakticheskaya Meditsina. 2012. No. 3. P. 17–21.
18. Tkachev A.V., Mkrtchyan L.S., Nikitina K.E., Volynskaya E.I. Inflammatory bowel disease: Crossing of the problems // Prakticheskaya Meditsina. 2012. No. 3. P. 17–21.
19. Burisch J., Munkholm P. The epidemiology of inflammatory bowel disease // Scand. J. Gastroenterol. 2015. Vol. 508. P. 942–951.
20. Burisch J., Munkholm P. The epidemiology of inflammatory bowel disease // Scand. J. Gastroenterol. 2015. Vol. 508. P. 942–951.
21. Colombel J.-F., Narula N., Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases // Gastroenterology. 2017. Vol. 152, No. 2. P. 351–361.
22. Colombel J.-F., Narula N., Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases // Gastroenterology. 2017. Vol. 152, No. 2. P. 351–361.
23. Dignass A., Van Assche G., Lindsay J.O. [at al.]. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management // Journal of Crohn’s and Colitis. 2010. Vol. 4. P. 28–62.
24. Dignass A., Van Assche G., Lindsay J.O. [at al.]. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management // Journal of Crohn’s and Colitis. 2010. Vol. 4. P. 28–62.
25. Dryden G.W. Optimizing the use of biologic therapies in the treatment of in flammator y bowel disease // Gastroenterol. Hepatol. 2015. Vol. 11, No. 12. P. 853–856.
26. Dryden G.W. Optimizing the use of biologic therapies in the treatment of in flammator y bowel disease // Gastroenterol. Hepatol. 2015. Vol. 11, No. 12. P. 853–856.
27. Jovani M., Danese S. Vedolizumab for the treatment of IBD: A selective therapeutic approach targeting pathogenic a4b7 cells // Curr. Drug. Targets. 2013. Vol. 14, No. 12. P. 1433–1443.
28. Jovani M., Danese S. Vedolizumab for the treatment of IBD: A selective therapeutic approach targeting pathogenic a4b7 cells // Curr. Drug. Targets. 2013. Vol. 14, No. 12. P. 1433–1443.
29. Molodecky N.A., Soon I.S., Rabi D.M. [et al.]. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review // Gastroenterology. 2012. Vol. 42, No. 1. P. 46–54.
30. Molodecky N.A., Soon I.S., Rabi D.M. [et al.]. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review // Gastroenterology. 2012. Vol. 42, No. 1. P. 46–54.
31. Van Assche G., Dignass A., Bokemeyer B. [at al.]. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease for the European Crohn’s and Colitis Organisation (ECCO) // Journal of Crohn,s and Colitis. 2012. doi: 10.1016/j.crohns.2012.09.005
32. Van Assche G., Dignass A., Bokemeyer B. [at al.]. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease for the European Crohn’s and Colitis Organisation (ECCO) // Journal of Crohn,s and Colitis. 2012. doi: 10.1016/j.crohns.2012.09.005
33. Yarur A.J., Strobel S.J., Deshpande A.R., Abreu M.T. Predictors of aggressive inflammatory bowel disease // Gastroenterol. Hepatol. 2011. Vol. 7, No. 10. Р. 652–659.
34. Yarur A.J., Strobel S.J., Deshpande A.R., Abreu M.T. Predictors of aggressive inflammatory bowel disease // Gastroenterol. Hepatol. 2011. Vol. 7, No. 10. Р. 652–659.
Review
For citations:
Evdokimova E.Yu., Chesnokova O.V., Mukhina I.L., Andreeva T.B., Moskalenko A.S., Saik O.V., Belova N.A. COMPLEX PROBLEMS OF TREATMENT OF INFLAMMATORY BOWEL DISEASES IN REAL-LIFE CLINICAL PRACTICE. Pacific Medical Journal. 2019;(3):76-79. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2019.3.76-79
Views:
3608
Email this article 